Walmsley Under Pressure Over GSK’s Strategy
Activist Investor Preparing To Pounce
GSK’s share price is down by 15% since Walmsley took over as CEO, but major investors are said to be resisting calls for a radical re-think in its strategy.
You may also be interested in...
The company is focusing on new technologies, including mRNA, and expects the vaccines business to deliver a high single-digit sales CAGR over the next five years.
In this week's podcast episode of Five Must-Know Things, hear about GSK coming under pressure from investors; BMS focusing on a promising oncology target in a new deal; Sanofi’s COVID-19 vaccine challenges; China's progress with mRNA coronavirus vaccines; and new headwinds for Pfizer’s Ibrance.
A CDC recommendation slowed non-pandemic vaccinations, but Shingrix shots will likely increase as more eligible consumers are fully vaccinated against SARS-CoV-2.